The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
If you liked this stock at a higher price, then you should sure as hell like it at this price.
Wouldn't be the first time the SP doesn't reflect value because of lack of communication about what is going on behind the scenes.
Another vision:
They are (legally) not allowed to share everything at every point in time. Some things need an RNS. They can't RNS every fart.
Besides that, they are now doing the last (regulatory) trials AND a trial designed to prove that they can detect live virus and thus detect infectiousness. There aren't much other test out there I can find that detect live virus. Ideal for infection control in hospitals and other controlled settings. COVID isn't going anywhere, the ones that truly believe that this test would be bought by the government for mass-testing strategy's need to adjust their expectations.
Bennster,
Also quote the context. You quoted the part that they ain't selling it as a COVID-test alone. Because, and quote: "Since the remaining potential partners and potential acquirers that Braveheart is in discussions with are interested in both the COVID and sepsis applications, it may be that a buyer or partner will still emerge in due course."
And the part about the value creation.
Braveheart's current share price has fallen in recent weeks, largely in response to a change in market sentiment towards 'COVID companies', which has impacted other quoted companies in this space.
Its a quote to not show the lack of value in Paraytec but to state that Paraytec isn't the only company in portfolio that has any value.
Please vote against the facility, as most of us here will probably do.
Bennster,
If you believe the CX300 is in the bottom drawer, I suggest you reread the RNS.
It only states they they aren't planning on selling the PLATFORM as just a covid-19 test. Why would they even continue the (costly) trial if its in the bottom drawer? Wait for the trial to finish, they will proof the efficacy of this test through this trial and that is necessary before they can even begin any partnership on good terms (rather then selling the test cheaply because any risk is a key driver to lower any license fee's).
And for the record, I am agreeing about the voting-against this proposal as a signal the the BOD. On the other hand, why would TB buy on open market if he was planning on doing a placing (probably against better terms).
Did anyone look at the timeline again?
They stated 6 mths after CMO-deal. In the latest RNS they only say that they are working with a company with the expertise to race products to markets (to a prototype that a CMO can produce).
Nothing on the CMO-deal or partner itself. For all we know, the clock is ticking already
I only check this board from time to time as it are always the same people that seem to have troubles with TB or BRH and keep posting here.
Hope y'all aren't like that IRL. Rather spend energy positively